Amphastar Pharmaceuticals Inc (AMPH) Position Raised by Skandinaviska Enskilda Banken AB publ
Skandinaviska Enskilda Banken AB publ lifted its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 6.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 152,300 shares of the company’s stock after purchasing an additional 9,200 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.33% of Amphastar Pharmaceuticals worth $2,930,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of AMPH. Principal Financial Group Inc. raised its holdings in Amphastar Pharmaceuticals by 2.2% in the 1st quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after acquiring an additional 5,789 shares during the last quarter. Meeder Asset Management Inc. raised its holdings in Amphastar Pharmaceuticals by 259.8% in the 2nd quarter. Meeder Asset Management Inc. now owns 10,486 shares of the company’s stock worth $160,000 after acquiring an additional 7,572 shares during the last quarter. Piedmont Investment Advisors LLC purchased a new position in Amphastar Pharmaceuticals in the 2nd quarter worth approximately $128,000. State of Wisconsin Investment Board raised its holdings in Amphastar Pharmaceuticals by 29.3% in the 2nd quarter. State of Wisconsin Investment Board now owns 36,200 shares of the company’s stock worth $552,000 after acquiring an additional 8,200 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in Amphastar Pharmaceuticals by 4.9% in the 2nd quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock worth $1,037,000 after acquiring an additional 3,193 shares during the last quarter. Institutional investors and hedge funds own 42.89% of the company’s stock.
In related news, Director Richard K. Prins sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $20.23, for a total value of $101,150.00. Following the completion of the transaction, the director now owns 40,434 shares of the company’s stock, valued at approximately $817,979.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO William J. Peters sold 38,484 shares of the company’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $20.74, for a total transaction of $798,158.16. Following the completion of the transaction, the chief financial officer now directly owns 106,636 shares of the company’s stock, valued at approximately $2,211,630.64. The disclosure for this sale can be found here. Insiders sold a total of 105,575 shares of company stock valued at $2,196,689 in the last ninety days. 31.50% of the stock is currently owned by insiders.
Shares of AMPH stock opened at $20.92 on Friday. Amphastar Pharmaceuticals Inc has a 1 year low of $14.40 and a 1 year high of $21.65. The company has a quick ratio of 1.34, a current ratio of 2.02 and a debt-to-equity ratio of 0.10. The firm has a market cap of $977.75 million, a PE ratio of 55.05, a price-to-earnings-growth ratio of 8.93 and a beta of 1.38.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, November 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. The company had revenue of $75.54 million during the quarter, compared to the consensus estimate of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 2.33% and a positive return on equity of 2.80%. Amphastar Pharmaceuticals’s quarterly revenue was up 30.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.07 EPS. On average, sell-side analysts forecast that Amphastar Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/11/16/amphastar-pharmaceuticals-inc-amph-position-raised-by-skandinaviska-enskilda-banken-ab-publ.html.
Amphastar Pharmaceuticals Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Featured Article: How to Invest in Growth Stocks
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.